Nautilus Biotechnology (NASDAQ:NAUT) Coverage Initiated by Analysts at Leerink Partners

Stock analysts at Leerink Partners initiated coverage on shares of Nautilus Biotechnology (NASDAQ:NAUT) in a research note issued on Wednesday, Briefing.com reports. The brokerage set an “outperform” rating and a $4.00 price target on the stock. Leerink Partners’ target price would suggest a potential upside of 304.04% from the stock’s current price.

Separately, Weiss Ratings cut Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.00.

Nautilus Biotechnology Price Performance

NASDAQ:NAUT traded up $0.06 during trading hours on Wednesday, hitting $0.99. 137,734 shares of the company were exchanged, compared to its average volume of 524,630. The stock has a market capitalization of $125.98 million, a price-to-earnings ratio of -2.22 and a beta of 0.87. Nautilus Biotechnology has a 52-week low of $0.68 and a 52-week high of $4.31. The company’s 50 day moving average price is $1.24 and its 200-day moving average price is $2.19.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Tuesday, July 28th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.10 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in shares of Nautilus Biotechnology by 37.1% during the 4th quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock worth $83,000 after acquiring an additional 13,363 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Nautilus Biotechnology in the 1st quarter worth about $194,000. Acadian Asset Management LLC boosted its position in Nautilus Biotechnology by 468.3% during the first quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock worth $51,000 after purchasing an additional 50,871 shares in the last quarter. XTX Topco Ltd boosted its position in Nautilus Biotechnology by 86.2% during the second quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock worth $48,000 after purchasing an additional 30,641 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in Nautilus Biotechnology in the second quarter valued at approximately $45,000. Hedge funds and other institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.